Anti-TNF-α therapy improves Treg and suppresses Teff in patients with rheumatoid arthritis
Anti-TNF-α therapies have been applied in RA treatment, but the regulatory effect of the drug
on immune system is not clear. In this study, we included 33 active RA patients and divided
them into two groups. One group received anti-TNF-α mAb+ methotrexate for 24weeks, the
other group got placebo+ methotrexate for the first 12weeks and anti-TNF-α mAb+
methotrexate for another 12weeks. Circulatory regulatory T cell (Treg) and effector T cell
(Teff) frequency was analyzed pre-therapy and week 12 and week 24 for both group patients …
on immune system is not clear. In this study, we included 33 active RA patients and divided
them into two groups. One group received anti-TNF-α mAb+ methotrexate for 24weeks, the
other group got placebo+ methotrexate for the first 12weeks and anti-TNF-α mAb+
methotrexate for another 12weeks. Circulatory regulatory T cell (Treg) and effector T cell
(Teff) frequency was analyzed pre-therapy and week 12 and week 24 for both group patients …